Nektar Therapeutics
NKTR
203 hedge funds and large institutions have $3.69B invested in Nektar Therapeutics in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 84 increasing their positions, 59 reducing their positions, and 16 closing their positions.
278% more call options, than puts
Call options by funds: $33.9M | Put options by funds: $8.97M
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
42% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 59
25% more capital invested
Capital invested by funds: $2.96B → $3.69B (+$733M)
3% more funds holding
Funds holding: 197 → 203 (+6)
0.06% more ownership
Funds ownership: 6.5% → 6.56% (+0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$32.5M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$20.8M |
| 3 |
BlackRock
New York
|
+$16.2M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$15.6M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$7.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PP
PDT Partners
New York
|
-$13M |
| 2 |
BM
Bridger Management
New York
|
-$11.2M |
| 3 |
O
OppenheimerFunds
New York
|
-$10.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$9.17M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$8.4M |
NKTR Hedge Fund Activity: Q3 2017 in Review
203 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2017, worth a combined $3.69B — up 25% from $2.96B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NKTR positions and 16 closed out — a net gain of 8 holders — while 84 added to existing stakes and 59 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $32.5M. The largest seller was PDT Partners, exiting entirely with an estimated $13M sold.
- 203 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2017, up from 197 in Q2 2017.
- Funds reported $3.69B of Nektar Therapeutics stock for Q3 2017, up 25% quarter-over-quarter.
- 24 funds opened new Nektar Therapeutics positions in Q3 2017 and 16 closed out, a net change of +8 holders.
- The largest Nektar Therapeutics buyer in Q3 2017 was Janus Henderson Group, an estimated $32.5M added.
- The largest Nektar Therapeutics seller in Q3 2017 was PDT Partners, an estimated $13M sold.
Based on aggregated 13F filings for Q3 2017.